Preliminary schedule

1. Afternoon Scientific session 13:30-18:00

13:30 Opening registration 

14:00 Welcome and opening of the symposium 

14:10 Highly pathogenic avian influenza H5 virus as a continuing pandemic threat  

        Prof. Ron Fouchier - Erasmus MC department of Viroscience

14:40 Organization of the National Reference Center for Respiratory pathogens: beyond detection to strengthening surveillance of bacterial and viral infections

        Dr. Lize Cuypers - Laboratorium voor Klinische Microbiologie, UZ Leuven 

15:00 SARI Surveillance 

         Ms. Yinthe Dockx - Sciensano 

15:20 Wastewater-based surveillance of respiratory viruses: integration to conventional surveillance systems in Belgium 

         Dr. Veronik Hutse - Sciensano 

15:40 Coffee break  

16:10 Mycoplasma pneumoniae and other respiratory bacteria

        Prof. dr. Pharm. biol. Veerle Matheeussen -  UZA 

16:35 Respiratory virus surveillance and real-world insight into intervention effectiveness: from genomic to using clinical virus isolates for phenotypic characterization

        Prof. Peter Delputte - ReViRAnt, UAntwerpen 

17:00 ​Pandemic preparedness: The importance of Controlled Human Infection (CHIM) studies for evaluating respiratory viral vaccines and therapeutics 

        dr. Bart Van Meerbergen - Vaccinopolis

17:25 Models and tools for research on respiratory viral infections

        dr. Koert Stittelaar - KULeuven 

2. Registration evening session and walking dinner 18:00-19:00

3. Evening policy and clinical session 19:00-20:55

19:00 Opening evening session 

19:10 RSV burden of disease in children: rational for prevention and current Belgian recommendations

       MD Sophie Blumental - Superior Health Council / CHIREC 

19:25 Preliminary results of the Belgian National Survey on RSV pediatric burden of disease

        MD Yves Lafort - Sciensano 

19:40 The AS01E-adjuvanted RSVPreF3 vaccine exhibits broad efficacy against diverse RSV strains

        dr. Lucile Warter - GSK 

19:55 Efficacy, effectiveness and clinical development programme of RSVpreF 

        MD Machteld De Bock and dr. Keliane Liberman - Pfizer 

20:10 Sanofi as partner in RSV prevention

        MD Patrick Dhont - Sanofi 

20:25 Update on MSDs advancements in RSV prevention 

        dr. Chloé Abels - MSD 

20:40 Monitoring mild and asymptomatic respiratory infections at the community level 

        Prof. dr. Emmanuel André - Laboratoriumgeneeskunde, UZ Leuven 

4. End of symposium and reception - 20:55 - 21:55